ATE168007T1 - Zur behandlung von erkrankungen des zentralnervensystems verwendbare benzimidazole - Google Patents

Zur behandlung von erkrankungen des zentralnervensystems verwendbare benzimidazole

Info

Publication number
ATE168007T1
ATE168007T1 AT94610012T AT94610012T ATE168007T1 AT E168007 T1 ATE168007 T1 AT E168007T1 AT 94610012 T AT94610012 T AT 94610012T AT 94610012 T AT94610012 T AT 94610012T AT E168007 T1 ATE168007 T1 AT E168007T1
Authority
AT
Austria
Prior art keywords
treatment
nervous system
central nervous
system diseases
disorders
Prior art date
Application number
AT94610012T
Other languages
English (en)
Inventor
Oskar Axelsson
Lene Teuber
Frank Waetjen
Original Assignee
Neurosearch As
Meiji Seika Kaisha
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DK33793A external-priority patent/DK33793D0/da
Priority claimed from DK105593A external-priority patent/DK105593D0/da
Application filed by Neurosearch As, Meiji Seika Kaisha filed Critical Neurosearch As
Application granted granted Critical
Publication of ATE168007T1 publication Critical patent/ATE168007T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/10—Radicals substituted by halogen atoms or nitro radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/06—Peri-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/06—Peri-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AT94610012T 1993-03-24 1994-03-11 Zur behandlung von erkrankungen des zentralnervensystems verwendbare benzimidazole ATE168007T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DK33793A DK33793D0 (da) 1993-03-24 1993-03-24 Nye receptoraktive forbindelser
DK105593A DK105593D0 (da) 1993-09-21 1993-09-21 Nye receptoraktive forbindelser

Publications (1)

Publication Number Publication Date
ATE168007T1 true ATE168007T1 (de) 1998-07-15

Family

ID=26063809

Family Applications (1)

Application Number Title Priority Date Filing Date
AT94610012T ATE168007T1 (de) 1993-03-24 1994-03-11 Zur behandlung von erkrankungen des zentralnervensystems verwendbare benzimidazole

Country Status (15)

Country Link
US (1) US5554632A (de)
EP (1) EP0616807B1 (de)
JP (1) JP3466265B2 (de)
KR (1) KR100297444B1 (de)
CN (1) CN1057088C (de)
AT (1) ATE168007T1 (de)
AU (1) AU675484B2 (de)
CA (1) CA2119511C (de)
DE (1) DE69411424T2 (de)
DK (1) DK0616807T3 (de)
ES (1) ES2119124T3 (de)
FI (1) FI113651B (de)
NO (1) NO306464B1 (de)
NZ (1) NZ260050A (de)
PH (1) PH31123A (de)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4332168A1 (de) * 1993-02-22 1995-03-23 Thomae Gmbh Dr K Cyclische Derivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
US5597940A (en) * 1994-03-16 1997-01-28 Sumitomo Chemical Company, Limited Process for producing β-nitroenamine
US5484794A (en) * 1994-11-09 1996-01-16 Eli Lilly And Company Method for treating anxiety
ES2150671T3 (es) * 1995-04-21 2000-12-01 Neurosearch As Compuesto de bencimidazol y su utilizacion como moduladores del complejo de receptores gaba-a.
EP0821684B1 (de) * 1995-04-21 2001-12-05 NeuroSearch A/S Benzmidazolverbindungen und ihre verwendung als modulatoren des gabaa-rezeptor-komplexes
AU714873B2 (en) 1995-08-02 2000-01-13 Newcastle University Ventures Limited Benzimidazole compounds
DE69739733D1 (de) 1996-10-21 2010-02-25 Neurosearch As 1-phenyl-benzimidazolverbindungen und ihre verwendung als modulatoren des gaba-a-rezeptors
GB9702524D0 (en) * 1997-02-07 1997-03-26 Merck Sharp & Dohme Therapeutic agents
WO1998045039A1 (en) * 1997-04-04 1998-10-15 The Regents Of The University Of California Polymerization catalysts containing electron-withdrawing amide ligands
CA2287255A1 (en) 1997-04-22 1998-10-29 Cocensys, Inc. Carbocyclic and heterocyclic substituted semicarbazones and thiosemicarbazones and the use thereof
EP1568690A1 (de) * 1997-04-22 2005-08-31 Euro-Celtique S.A. Durch carbozyklische und heterozyklische substituierte Semicarbazone und Thiosemicarbazone und ihre Anwendung als Natriumkanalblocker
WO1999006394A1 (de) * 1997-07-14 1999-02-11 Basf Aktiengesellschaft Substituierte 2-(benzaryl)pyridine
US5990146A (en) 1997-08-20 1999-11-23 Warner-Lambert Company Benzimidazoles for inhibiting protein tyrosine kinase mediated cellular proliferation
US6465484B1 (en) 1997-09-26 2002-10-15 Merck & Co., Inc. Angiogenesis inhibitors
EP1017682A4 (de) * 1997-09-26 2000-11-08 Merck & Co Inc Neue angiogenese-inhibitoren
US6162804A (en) * 1997-09-26 2000-12-19 Merck & Co., Inc. Tyrosine kinase inhibitors
JP2001519429A (ja) * 1997-10-10 2001-10-23 ニューロサーチ、アクティーゼルスカブ ベンズイミダゾール化合物、この化合物を含む医薬組成物、およびそれらの使用
US6365589B1 (en) 1998-07-02 2002-04-02 Bristol-Myers Squibb Pharma Company Imidazo-pyridines, -pyridazines, and -triazines as corticotropin releasing factor antagonists
AU4652699A (en) * 1998-07-15 2000-02-07 Meiji Seika Kaisha Ltd. Process for producing 4-substituted-2-nitro-fluorobenzenes
CA2348234A1 (en) * 1998-10-29 2000-05-11 Chunjian Liu Compounds derived from an amine nucleus that are inhibitors of impdh enzyme
US6380210B1 (en) 1999-04-02 2002-04-30 Neurogen Corporation Heteroaryl fused aminoalkyl-imidazole derivatives: selective modulators of GABAa receptors
US6271241B1 (en) 1999-04-02 2001-08-07 Neurogen Corporation Cycloalkyl and aryl fused aminoalkyl-imidazole derivatives: modulators and GLP-1 receptors
US6281237B1 (en) 1999-04-02 2001-08-28 Neurogen Corporation N-phenyl benzimidazolecarboxamide and N-phenyl indolecarboxamide derivatives
ATE277927T1 (de) * 1999-04-02 2004-10-15 Neurogen Corp Aryl- und heteroaryl-kondensierte aminoalkyl- imidazol-derivate: selektive modulatoren der gabaa-rezeptoren
US6627624B1 (en) 1999-04-02 2003-09-30 Neurogen Corporation Aryl fused aminoalkyl-imidazole derivatives: selective modulators of GABAa receptors
RU2243226C2 (ru) * 1999-06-22 2004-12-27 НьюроСёрч А/С Новые производные бензимидазола и содержащие эти соединения фармацевтические композиции
NZ517221A (en) * 1999-08-19 2004-01-30 Nps Pharma Inc Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists
GB9921150D0 (en) 1999-09-07 1999-11-10 Merck Sharp & Dohme Therapeutic agents
US7217722B2 (en) * 2000-02-01 2007-05-15 Kirin Beer Kabushiki Kaisha Nitrogen-containing compounds having kinase inhibitory activity and drugs containing the same
US6642229B2 (en) 2000-05-24 2003-11-04 Merck Sharp & Dohme Ltd. 3-Phenyl-imidazo-pyrimidine derivatives as ligands for GABA receptors
GB0208394D0 (en) * 2002-04-11 2002-05-22 Merck Sharp & Dohme Therapeutic agents
US7115644B2 (en) 2002-09-13 2006-10-03 Boehringer Ingelheim Pharmaceuticals Inc. Heterocyclic compounds
EP1613312B1 (de) * 2003-04-03 2008-02-20 Neurosearch A/S Benzimidazole derivate und ihre anwendung als gaba a rezeptor komplex modulatoren
WO2004087690A2 (en) 2003-04-03 2004-10-14 Neurosearch A/S Benzimidazole derivatives and their use for modulating the gaba-a receptor complex
US7060723B2 (en) * 2003-08-29 2006-06-13 Allergan, Inc. Treating neurological disorders using selective antagonists of persistent sodium current
US7125908B2 (en) * 2003-08-29 2006-10-24 Allergan, Inc. Treating pain using selective antagonists of persistent sodium current
WO2005040131A1 (en) * 2003-10-23 2005-05-06 Akzo Nobel N.V. 1,5,7-trisubstituted benzimidazole derivatives and their use for modulating the gabaa receptor complex
WO2005121132A1 (ja) * 2004-06-11 2005-12-22 Shionogi & Co., Ltd. 抗ｈｃｖ作用を有する縮合ヘテロ環化合物
CN101223145A (zh) * 2005-07-11 2008-07-16 出光兴产株式会社 具有吸电子性取代基的含氮杂环衍生物以及使用其的有机电致发光元件
US20080312303A1 (en) * 2005-10-14 2008-12-18 Neurosearch A/S Imidazole Derivatives and Their Use for Modulating the Gabaa Receptor Complex
TWI391381B (zh) 2006-03-24 2013-04-01 Neurosearch As 新穎的苯并咪唑衍生物、含有其之醫藥組成物、及其於製造藥物之用途
CN101835747A (zh) 2007-07-24 2010-09-15 安斯泰来制药有限公司 苯并咪唑衍生物
TW201029987A (en) * 2008-11-14 2010-08-16 Neurosearch As Novel compounds
WO2010055126A1 (en) * 2008-11-14 2010-05-20 Neurosearch A/S Benzimidazole derivatives and their use for modulating the gabaa receptor complex
WO2010055133A1 (en) * 2008-11-14 2010-05-20 Neurosearch A/S Benzimidazole derivatives and their use for modulating the gabaa receptor complex
TW201029986A (en) * 2008-11-14 2010-08-16 Neurosearch As Novel compounds
WO2010055130A1 (en) * 2008-11-14 2010-05-20 Neurosearch A/S Benzimidazole derivatives and their use for modulating the gabaa receptor complex
WO2010055127A1 (en) * 2008-11-14 2010-05-20 Neurosearch A/S Benzimidazole derivatives and their use for modulating the gabaa receptor complex
EP2383573A4 (de) 2009-01-27 2012-10-24 Astellas Pharma Inc Screening-verfahren für eine als mittel zur behandlung von prostatakrebs verwendbare substanz
WO2011047315A1 (en) 2009-10-15 2011-04-21 Concert Pharmaceuticals, Inc. Subsitituted benzimidazoles
WO2012142208A1 (en) * 2011-04-13 2012-10-18 The Trustees Of The University Of Pennsylvania Bifunctional akr1c3 inhibitors/androgen receptor modulators and methods of use thereof
WO2013123215A2 (en) * 2012-02-17 2013-08-22 Siga Technologies, Inc. Antiviral drugs for treatment of arenavirus infection
EP3666770A4 (de) * 2017-08-07 2021-04-07 Joint Stock Company "Biocad" Neue heterozyklische verbindungen als cdk8/19-inhibitoren
CA3110283A1 (en) 2018-09-13 2020-03-19 Saniona A/S A gaba a receptor ligand

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PH31175A (en) * 1990-10-31 1998-03-20 Squibb & Sons Inc Indole and benzimi-dazole-substituted imidazole and benzimidazole derivatives.
ATE163290T1 (de) * 1991-06-24 1998-03-15 Neurosearch As Imidazol-verbindungen, verfahren zu ihrer herstellung und ihre anwendung
US5158969A (en) * 1991-08-21 1992-10-27 Neurosearch A/S Indole derivatives as potassium channel blockers
DK40192D0 (da) * 1992-03-26 1992-03-26 Neurosearch As Imidazolforbindelser, deres fremstilling og anvendelse

Also Published As

Publication number Publication date
NO941052D0 (no) 1994-03-23
CA2119511C (en) 2002-07-16
PH31123A (en) 1998-02-23
US5554632A (en) 1996-09-10
NO306464B1 (no) 1999-11-08
FI113651B (fi) 2004-05-31
FI941378A0 (fi) 1994-03-24
FI941378A (fi) 1994-09-25
NO941052L (no) 1994-09-26
CA2119511A1 (en) 1994-09-25
EP0616807A1 (de) 1994-09-28
DE69411424T2 (de) 1999-01-28
AU675484B2 (en) 1997-02-06
NZ260050A (en) 1996-01-26
CN1057088C (zh) 2000-10-04
DE69411424D1 (de) 1998-08-13
KR100297444B1 (ko) 2001-10-24
ES2119124T3 (es) 1998-10-01
JP3466265B2 (ja) 2003-11-10
AU5752194A (en) 1994-09-29
CN1099391A (zh) 1995-03-01
KR940021533A (ko) 1994-10-19
JPH072838A (ja) 1995-01-06
DK0616807T3 (da) 1999-04-19
EP0616807B1 (de) 1998-07-08

Similar Documents

Publication Publication Date Title
ATE168007T1 (de) Zur behandlung von erkrankungen des zentralnervensystems verwendbare benzimidazole
ATE210654T1 (de) Tricyclische amide und harnstoffderivate zur inhibierung der g-protein funktion und für die behandlung von proliferatinen erkrankungen
ES2078440T3 (es) Compuestos farmaceuticos.
ATE211743T1 (de) Substituierte 3-aminochinuclidine
DE69523155D1 (de) Benzimidazolonderivate mit zentraler dopaminerger aktivität
ATE79257T1 (de) Verwendung von tetrahydrobenz(c,d>indol-6carboxamiden zur herstellung von arzneimitteln zur behandlung von angstzustaenden.
ATE69049T1 (de) Chinazolin-derivat, verfahren zu dessen herstellung und mittel zur behandlung von cerebraler disfunktion als aktiver inhaltsstoff.
ATE294584T1 (de) Verwendung von desoxypeganin zur behandlung von alzheimerischer demenz
ATE345344T1 (de) (oxopyrazolo 1,5aöpyrimidin-2-yl) alkylcarbonsäureamide
ATE250027T1 (de) Azetidincarboxamidderivate zur behandlung von zns-erkrankungen
FI943875A (fi) 2,3,4,5-Tetrahydro-1H-3-bentsatsepiinejä ja niiden farmaseuttisesti hyväksyttäviä happoadditiosuoloja
ATE283269T1 (de) 5-(heteroaryl)alkyl)-3-oxo-pyrido(1,2- a)benzimidazol-4-carboxamid (pbi) derivate zur behandlung von störungen des zentralen nervensystems
DE69902142D1 (de) Azetidincarboxamidderivate zur behandlung von zns-erkrankungen
ATE264840T1 (de) Azetidincarboxamid-derivate zur behandlung von zns störungen
DE69619088T2 (de) Quinoxalin-Derivate zur Behandlung von Tinnitus
ATE230608T1 (de) Verwendung von bradykinin-antagonisten zur herstellung von arzneimitteln zur behandlung und prävention der alzheimer'schen krankheit
MA23773A1 (fr) PROCEDE BIOLOGIQUE D'EPURATION DES EAUX USEES "bioseptis"
TH64560A (de)

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
EEIH Change in the person of patent owner
REN Ceased due to non-payment of the annual fee